Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
LMAT 
LeMaitre Vascular Inc (LMAT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: LMAT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $104.5
1 Year Target Price $104.5
| 3 | Strong Buy |
| 2 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 12.18% | Avg. Invested days 47 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.87B USD | Price to earnings Ratio 41.91 | 1Y Target Price 104.5 |
Price to earnings Ratio 41.91 | 1Y Target Price 104.5 | ||
Volume (30-day avg) 11 | Beta 0.82 | 52 Weeks Range 71.25 - 109.05 | Updated Date 06/29/2025 |
52 Weeks Range 71.25 - 109.05 | Updated Date 06/29/2025 | ||
Dividends yield (FY) 0.97% | Basic EPS (TTM) 1.97 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 19.96% | Operating Margin (TTM) 21.09% |
Management Effectiveness
Return on Assets (TTM) 7.28% | Return on Equity (TTM) 13.77% |
Valuation
Trailing PE 41.91 | Forward PE 37.88 | Enterprise Value 1748428470 | Price to Sales(TTM) 8.25 |
Enterprise Value 1748428470 | Price to Sales(TTM) 8.25 | ||
Enterprise Value to Revenue 7.73 | Enterprise Value to EBITDA 25.1 | Shares Outstanding 22594400 | Shares Floating 20653958 |
Shares Outstanding 22594400 | Shares Floating 20653958 | ||
Percent Insiders 8.83 | Percent Institutions 94.91 |
Analyst Ratings
Rating 4 | Target Price 104.5 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold 6 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
LeMaitre Vascular Inc
Company Overview
History and Background
LeMaitre Vascular Inc. was founded in 1983. Initially focused on manufacturing valvulotomes, they have expanded into a diversified vascular surgery device company through internal development and acquisitions.
Core Business Areas
- Peripheral Vascular: Devices used in procedures to treat peripheral artery disease (PAD), including grafts, valves, and embolectomy catheters.
- Cardiovascular: Products for cardiac surgery, such as valvuloplasty balloons and aortic connectors.
- Hemodialysis: Devices used in creating and maintaining access for hemodialysis, including grafts and catheters.
- Surgical: Valvulotomes and other essential vascular surgical tools
Leadership and Structure
The leadership team includes George W. LeMaitre (Chairman & CEO) and Joseph Pellegrino (President & COO). The company has a functional organizational structure with departments for R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- XenoSure Biologic Patches: Used for cardiovascular and vascular reconstruction. Competitors include Baxter and Getinge. Market share and revenue data is proprietary.
- ProxiSure Anastomotic System: Designed for proximal anastomosis in coronary artery bypass grafting (CABG). Competitors include Medtronic. Market share and revenue data is proprietary.
- Inari Catheters: Used for removal of clots in peripheral vessels (licensed from Inari Medical). Market share and revenue data is proprietary.
Market Dynamics
Industry Overview
The vascular surgery device market is driven by an aging population, increasing prevalence of vascular diseases, and technological advancements. It is characterized by moderate growth and increasing competition.
Positioning
LeMaitre Vascular Inc. focuses on niche segments within the vascular surgery device market, often targeting procedures where specialized devices can improve outcomes. Their competitive advantage lies in their specialized product portfolio and strong relationships with vascular surgeons.
Total Addressable Market (TAM)
The total addressable market for vascular surgery devices is estimated to be in the billions of dollars. LeMaitre is positioned to capture a portion of the market by providing unique specialized tools.
Upturn SWOT Analysis
Strengths
- Specialized product portfolio
- Strong relationships with vascular surgeons
- History of successful acquisitions
- Established distribution network
- Focus on niche markets
Weaknesses
- Limited scale compared to larger competitors
- Reliance on a few key products
- Exposure to reimbursement pressures
- Product liability risks
- High acquisition debt
Opportunities
- Expanding into new geographic markets
- Developing new products through internal R&D
- Acquiring complementary businesses
- Capitalizing on technological advancements
- Partnering with larger medical device companies
Threats
- Increased competition from larger players
- Pricing pressures from hospitals and insurers
- Regulatory changes
- Product recalls
- Economic downturns
Competitors and Market Share
Key Competitors
- MDT
- BSX
- JNJ
- BDX
- ABT
Competitive Landscape
LeMaitre Vascular Inc. competes with larger medical device companies by focusing on niche markets and specialized products. They need to stay focused on innovation and maintain strong relationships with vascular surgeons. Market share is highly fragmented.
Major Acquisitions
Artegraft, Inc.
- Year: 2023
- Acquisition Price (USD millions): 90
- Strategic Rationale: Expands LeMaitre's biologic graft portfolio.
Prolucid Technologies, Inc.
- Year: 2018
- Acquisition Price (USD millions): 19
- Strategic Rationale: Adds flow control valves for carotid artery shunt.
Growth Trajectory and Initiatives
Historical Growth: LeMaitre Vascular Inc. has grown through a combination of organic growth and acquisitions.
Future Projections: Future growth projections vary depending on who you ask. See the latest analyst reports.
Recent Initiatives: Recent strategic initiatives include product launches, geographic expansion, and acquisitions.
Summary
LeMaitre Vascular Inc. is a strong niche player in the vascular surgery device market. It has a solid product portfolio and successful acquisition history. Continued innovation and addressing debt from acquisitions are important. Reimbursement pressures and competition from larger companies are factors to watch out for.
Peer Comparison
Sources and Disclaimers
Data Sources:
- LeMaitre Vascular Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated based on available information and may not be precise. Financial data is based on past performance and is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About LeMaitre Vascular Inc
Exchange NASDAQ | Headquaters Burlington, MA, United States | ||
IPO Launch date 2006-10-19 | Chairman & CEO Mr. George W. LeMaitre | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 651 | Website https://www.lemaitre.com |
Full time employees 651 | Website https://www.lemaitre.com | ||
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It also provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular and porcine patches; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.